Status:

COMPLETED

Galantamine for Cognition in People With Schizophrenia

Lead Sponsor:

North Suffolk Mental Health Association

Collaborating Sponsors:

Janssen Medical Affairs

Conditions:

Schizophrenia

Schizoaffective Disorder

Eligibility:

All Genders

18-60 years

Phase:

PHASE4

Brief Summary

This study is a double-blind, placebo-controlled trial of the nicotinic receptor agonist, galantamine, for the improvement of memory and attention in people with schizophrenia and schizoaffective diso...

Detailed Description

Background: Galantamine is a novel acetylcholinesterase inhibitor that is also a positive allosteric modulator of nicotinic acetylcholine receptors. Galantamine has been shown to increase conductivit...

Eligibility Criteria

Inclusion

  • Diagnosis of schizophrenia or schizoaffective disorder depressed type with stable psychiatric symptoms, no active suicidal ideation
  • Age 18-60, inclusive
  • Stable medical conditions such as hypertension, non-insulin-dependent diabetes, hypothyroidism allowed
  • Treated with antipsychotic medications at a stable dose for \> 4 weeks
  • Not treated with investigational medications in the past 30 days
  • Competent to provide informed consent
  • WRAT-3 IQ raw score greater than or equal to 35
  • Expired CO level \< 9 ppm
  • Salivary cotinine level \< 30 ng/ml
  • Non-smoker for at least 3 months

Exclusion

  • Diagnosis of dementia, neurodegenerative disease or any other current Axis I DSM-IV diagnosis
  • Any unstable medical illness, asthma requiring daily treatment, severe COPD, active peptic ulcer disease, gastrointestinal bleeding, atrioventricular block, urinary outflow obstruction, history of epilepsy
  • Concurrent use of anticholinergic medications or use of cholinomimetic medications in the past month, such as cogentin, donepezil or clozapine
  • Alcohol or substance abuse in the past month (self-report and confirmed by chart)
  • Known allergy or hypersensitivity to galantamine
  • Current treatment with erythromycin or ketoconazole
  • Concurrent use of NSAIDs
  • Women of childbearing potential
  • History of suicide attempt in the past year

Key Trial Info

Start Date :

January 1 2004

Trial Type :

INTERVENTIONAL

End Date :

May 1 2006

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00320736

Start Date

January 1 2004

End Date

May 1 2006

Last Update

May 19 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Freedom Trail Clinic

Boston, Massachusetts, United States, 02114